MA52894A - 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci - Google Patents

19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci

Info

Publication number
MA52894A
MA52894A MA052894A MA52894A MA52894A MA 52894 A MA52894 A MA 52894A MA 052894 A MA052894 A MA 052894A MA 52894 A MA52894 A MA 52894A MA 52894 A MA52894 A MA 52894A
Authority
MA
Morocco
Prior art keywords
disubstituted
steroid
pyrazolyl
methods
same
Prior art date
Application number
MA052894A
Other languages
English (en)
Inventor
James J Doherty
Handan Gunduz-Bruce
Jeffrey M Jonas
Stephen Jay Kanes
Robert Alfonso Lasser
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MA52894A publication Critical patent/MA52894A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052894A 2018-06-12 2019-06-12 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci MA52894A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684155P 2018-06-12 2018-06-12
US201962789329P 2019-01-07 2019-01-07
US201962841645P 2019-05-01 2019-05-01

Publications (1)

Publication Number Publication Date
MA52894A true MA52894A (fr) 2021-04-21

Family

ID=67211854

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052894A MA52894A (fr) 2018-06-12 2019-06-12 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci

Country Status (13)

Country Link
US (4) US20210338692A1 (fr)
EP (1) EP3806863A1 (fr)
JP (3) JP2021527092A (fr)
KR (1) KR20210021005A (fr)
CN (2) CN117959309A (fr)
AU (2) AU2019287491B2 (fr)
CA (1) CA3103421A1 (fr)
IL (1) IL279315A (fr)
MA (1) MA52894A (fr)
MX (2) MX2020013557A (fr)
SG (1) SG11202012344RA (fr)
TW (1) TWI923545B (fr)
WO (1) WO2019241442A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (fr) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions et procédés pour traiter des troubles du snc
WO2018013613A1 (fr) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US20230018765A1 (en) * 2019-12-05 2023-01-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CN115551514A (zh) 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途
CA3187178A1 (fr) * 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations de steroide c21-n-pyrazolyle 19-nor c3,3-disubstitue et leurs procedes d'utilisation
WO2022165017A1 (fr) * 2021-01-28 2022-08-04 Sage Therapeutics, Inc. Utilisation de stéroïdes neuroactifs pour le traitement d'une dysfonction sexuelle
JP2024510436A (ja) * 2021-03-17 2024-03-07 セージ セラピューティクス， インコーポレイテッド 大うつ病性障害の処置のための１９－ノルｃ３，３－２置換ｃ２１－ｎ－ピラゾリルステロイド
MX2023012728A (es) * 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante.
MX2023012727A (es) * 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
JP2025508406A (ja) * 2022-02-16 2025-03-26 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ関連障害を処置するための神経活性ステロイド
WO2025175214A1 (fr) * 2024-02-16 2025-08-21 Engrail Therapeutics, Inc. Méthodes de traitement d'un trouble d'anxiété généralisée

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) * 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US20170233433A1 (en) * 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
PH12018501923B1 (en) * 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
TW202604538A (zh) * 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (fr) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Stéroïdes neuroactifs et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
US20200113917A1 (en) 2020-04-16
AU2019287491B2 (en) 2025-05-15
CN112533611A (zh) 2021-03-19
US20210338692A1 (en) 2021-11-04
JP2025108553A (ja) 2025-07-23
MX2020013557A (es) 2021-05-27
TW202005653A (zh) 2020-02-01
SG11202012344RA (en) 2021-01-28
US20220323462A1 (en) 2022-10-13
EP3806863A1 (fr) 2021-04-21
JP2021527092A (ja) 2021-10-11
AU2025217363A1 (en) 2025-09-04
CA3103421A1 (fr) 2019-12-19
US20250339447A1 (en) 2025-11-06
MX2025000166A (es) 2025-03-07
TWI923545B (zh) 2026-05-01
CN117959309A (zh) 2024-05-03
KR20210021005A (ko) 2021-02-24
JP2024028849A (ja) 2024-03-05
AU2019287491A1 (en) 2021-01-07
WO2019241442A1 (fr) 2019-12-19
IL279315A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA45599A (fr) Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
EP3950716A4 (fr) Anticorps anti-claudine 18.2 et utilisation associée
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
EP3878863A4 (fr) Anticorps anti-claudin18.2 et son utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
IL279315A (en) 19-NOR C3,3-dimuter C21-N-pyrazolyl steroid and methods of using it
EP3495391A4 (fr) Anticorps dirigé contre le ligand 1 de mort programmée (pd-l1) et son utilisation
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3746211A4 (fr) Dispositifs, procédés et kits de caractérisation d'échantillon
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
EP3707158A4 (fr) Biomarqueurs du cancer et leurs procédés d'utilisation
EP3757563A4 (fr) Procédé, dispositif et programme de test ultrasonore, et système de test ultrasonore
EP3807348A4 (fr) Gels cellulosiques, films et composites comprenant les gels, et procédés de formation de ceux-ci
EP3801574A4 (fr) Procédés d'édition génomique et d'activation de cellules
ZA202206670B (en) Anti-ly6g6d antibodies and methods of use
IL278926A (en) Antibodies specific to CD3 and their uses
EP3621660A4 (fr) Compositions et procédés d'utilisation de capsides arc
MA52416A (fr) Anticorps b7-h4 et leurs procédés d'utilisation
EP4054765A4 (fr) Systèmes microfluidiques numériques, appareils et procédés d'utilisation de ceux-ci
EP3464346A4 (fr) Anticorps, composition et kits les comprenant et leurs procédés d'utilisation
SG10201907405QA (en) Method of operating storage device, storage device performing the same and storage system including the same